Pulmonary hypertension (PH) is a complex, progressive condition characterized by elevated pulmonary artery pressure and pulmonary vascular resistance. This article provides a comprehensive overview of the fundamental aspects of PH, including its pathophysiology, diagnosis, and management strategies.
PH is primarily a disorder of the pulmonary vasculature. It is characterized by vasoconstriction, vascular remodeling, and in situ thrombosis. These changes lead to increased pulmonary vascular resistance and subsequently elevated pulmonary artery pressure. The disease is classified into five groups based on the underlying cause, each with distinct pathophysiological mechanisms.
Diagnosis of PH involves a combination of clinical evaluation, echocardiography, and right heart catheterization. Echocardiography is a non-invasive tool used for initial assessment, while right heart catheterization is the gold standard for confirming the diagnosis. Additional tests such as pulmonary function tests, chest radiographs, and CT scans may be required to identify the underlying cause.
Treatment of PH is multifaceted and depends on the underlying cause. General measures include lifestyle modifications, oxygen therapy, and anticoagulation. Specific therapies target the three main pathways involved in the pathogenesis: the nitric oxide, endothelin, and prostacyclin pathways. Lung transplantation may be considered in severe, refractory cases.
PH is a complex disease with a multifactorial pathogenesis and diverse clinical manifestations. Understanding its fundamentals is crucial for its early diagnosis and effective management. As physicians, maintaining a high index of suspicion and adopting a systematic approach to diagnosis can significantly improve patient outcomes. Continuous research in this field is essential to develop more effective therapeutic strategies.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation